Developments in clinical trials and health information technology that will improve targeted therapies for patients
Developments in clinical trials and health information technology that will improve targeted therapies for patients
Dasatinib plus intensive chemo versus stem cell transplant for Philadelphia chromosome positive ALL
Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma
Raloxifene retained approximately 81% of the effectiveness of tamoxifen in preventing invasive breast cancer
Next generation inhibitors help overcome problems of resistance in ALK positive lung cancer
Transarterial chemoembolization with or without sorafenib for intermediate-stage hepatocellular carcinoma
Letrozole vs observation for HR positive breast cancer
Preventive neck lymph node surgery improves early oral cancer survival
Preventive neck lymph node surgery improves early oral cancer survival
Phase III study finds initial nivolumab-based treatment halts melanoma progression
New targeted treatments for blood cancers: Multiple myeloma, non-Hodgkin lymphoma, genomic marker mismatch repair and myelofibrosis
Targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma